Many of the available oral antidiabetes agents, as well as insulin, are associated with weight gain that contribute to an increase in CV risk and insulin resistance (table 3) [20,25] thereby creating a significant challenge in the management of overweight/obese patients with type 2 diabetes. The gene discussed is INS; the disease is type 2 diabetes mellitus.